BCRX241220C9000
- 0.01
- -0.04-80.00%
BioCryst Pharmaceuticals Newsroom
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
KalVista Wins New Buy at BofA on Potential of Lead Candidate
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Institutional Investors Lost 5.5% Last Week but Have Benefitted From Longer-term Gains
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator
BioCryst Launches ORLADEYO (Berotralstat) in Ireland
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst (BCRX) Receives a Buy From Bank of America Securities
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharma Analyst Ratings
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | BioCryst Pharmaceuticals, Inc. : Barclays Raises Target Price to $8 From $7